11月 2025
- 首頁
- RECORDATI
11月 2025RECORDATI的市場佔有率分析
Chemicals Business We manufacture and provide our Active Pharmaceutical Ingredient (API) portfolio to customers worldwide. Recordati has a long-standing track record within its chemical division, with strong internal capabilities, internationally recognised quality products and long-term relationships with our customers. Our Active Principles cover several therapeutic areas in both primary and specialty care, meeting the… Continue reading Our Business – Chemicals Business
RECORDATI(包含公司地區)
查看更多網站流量與參與度資訊- recordati.it
RECORDATI截至 11月 2025 的總收入為 > 1B
RECORDATI 熱門網域產生的總收入
RECORDATI 熱門網域 3 年內的總收入
RECORDATI 熱門網域的總收入
11月 2025RECORDATI的股票價格
RECORDATI 股票交易代碼 #REC。以下是截至 11月 2025RECORDATI 過去 12 個月的股票績效
RECORDATI的熱門網域總造訪量
了解RECORDATI市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
RECORDATI的熱門網域平均造訪時長
分析RECORDATI參與度指標。
過去 3 個月平均造訪時長
子公司細目
RECORDATI的熱門網域平均頁面瀏覽量
了解RECORDATI如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自RECORDATI
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Recordati S.p.A. acquired EUSA Pharma Ltd for $824M on Mar 1st '22.In March 2022, Recordati S.p.A., an Italy-based pharmaceutical group, acquired EUSA Pharma (UK) Ltd. for $824.28 million.
6月 11, 2023閱讀更多
新聞Astrazeneca partnered with Recordati S.p.A. on May 1st '17.AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, headquartered in the U.K., announced that it has partnered up with Recordati, an Italy-based pharmaceutical company in May 2017.
11月 3, 2020閱讀更多
新聞Recordati S.p.A. partners with Novelion Therapeutics Inc..In February, Recordati signed a license agreement with Aegerion Pharmaceuticals Inc. for the exclusive rights to commercialize Juxtapid®, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan.
7月 30, 2019閱讀更多
查看所有RECORDATI信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。